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Abstract: Lyme disease (LD) is the most prevalent tick-borne disease in Europe. LD is caused by the spirochete
Borrelia burgdorferi. LD is a chronic disease which can attack a number of organs: skin, heart, brain, joints.
Chronic, low-grade inflammation involves general production of pro-inflammatory cytokines and inflammatory
markers and is a typical feature of aging. So far, the best method of diagnosing LD is a time-consuming and
expensive two-stage serological method. The aim of our study was to evaluate the activity of two lysosomal
exoglycosidases: a-fucosidase (FUC) and b-galactosidase (GAL) in the serum of patients with Lyme disease, as
potential markers of LD. Due to the increasing number of patients with Lyme disease and a number of false
results, new ways to diagnose this disease are still being sought. As elevated level of b-galactosidase is a manifes-
tation of residual lysosomal activity in senescent cells, the increase in its activity in serum during chronic Lyme
disease might be a marker of a potentially accelerated senescence process. The study was performed on serum
taken from cubital veins of 15 patients with Lyme disease and eight healthy subjects (control group). FUC and
GAL activity was measured by the method of Chatterjee et al. as modified by Zwierz et al. In the serum of
patients with Lyme disease, GAL activity significantly increased (p = 0.029), and the activity of FUC had
a tendency to increase (p = 0.153), compared to the control group. A significant increase in GAL activity in the
serum of patients with Lyme disease indicates an increased catabolism of glycoconjugates (glycoproteins, gly-
colipids, proteoglycans) and could be helpful in the diagnosis of Lyme disease, although this requires confirma-
tion in a larger group of patients. As GAL is the most widely used assay for detection of senescent cells, an
elevated level of b-galactosidase might be a manifestation of accelerated senescence process in the course of
Lyme disease. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 2, 270–274)
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Introduction
Lyme disease (LD) is a bacterial disease caused by
the spirochete Borrelia burgdorferi, transferred to hu-
mans by infected Ixodes ricinus ticks [1–3]. After the
bite of a Borrelia burgdorferi infected tick, spirochetes
penetrate human skin within 48 hours, and after 72
hours the risk of infection is 100% [4]. Lyme disease
is endemic in Europe, America and northern regions
of Asia [5]. In Europe, LD is most common in the
forested areas of Scandinavia, and Central Europe,
especially Germany, Austria, and Slovenia [6]. In
Poland, LD is the commonest tick-borne disease and
is becoming a serious epidemiological problem [7].
Australia, Africa, South America and southern parts
of the United States are considered free of the dis-
ease [5]. In Poland, the biggest threat of Lyme dis-
ease occurs in forested areas: Podlasie, Maritime
Province, West Polish Lake District, Carpathian
Mountains, and Karkonosze [6]. Exposure to Lyme
disease involves those in endemic areas, mostly for-
estry workers, collectors of wild products in the for-
ests, as well as tourists visiting forest areas [5, 7]. The
disease occurs with similar frequency in men and
women and can develop at any age [5]. Lyme disease
is characterized by a broad spectrum of symptoms in
many organs involved: skin, heart, brain and joints
[1]. So far, the best method of diagnosing LD is
a time-consuming and expensive two-stage serologi-
cal method. Due to an increasing number of patients
with Lyme disease and a number of false results, new
ways to diagnose LD are still being sought. Our re-
search is based on the fact that Borrelia burgdorferi
associates with epithelial glycosaminoglycans (com-
ponents of proteoglycans) and glycosphingolipids lo-
cated on the surface of neuronal cells [8]. It is known
that Borrelia burgdorferi infection causes an immuno-
logical response. Immunological response provokes
increase in metabolism of the glycoconjugates (gly-
coproteins, glycolipids and proteoglycans) [9, 10],
which constitute cell membranes and extracellular
matrix [11]. Beta-GAL expression has been shown to
be a reliable indicator of the switch mechanism used
by cells to enter senescence [12]. The senescent phe-
notype displays distinct morphological characteristics
where cells become enlarged and flattened with in-
creased granularity and a vacuole-rich cytoplasm [13].
Catabolism of glycoconjugates occurs in lysos-
omes. In lysosomes the protein parts of glycoconju-
gates are degraded by proteases and sugar chains by
glycosidases, which include a-fucosidase (FUC), and
b-galactosidase (GAL) [14].
FUC is a lysosomal exoglycosidase [15], which
cleaves a-fucose from oligosaccharides [14, 16]. Par-
ticipation of lysosomal FUC is essential in the catab-
olism of glycoproteins and complex fucoglycolipids
e.g. blood group substances [17]. It has been shown
that the presence of FUC correlates with the expres-
sion of Lewis x (Lexx) antigen [16]. Approximately
10–15% of the total FUC activity is located on the
surface of human cells (mesenchymal and liver cells)
[18]. FUC is characterized by considerable tissue het-
erogeneity. In the body, FUC is present in specific
tissues, but some tissues do not contain the alleles of
the gene for FUC [18].
GAL (commonly known as lactase) participates
in catabolism of glycoconjugates possessing D-galac-
tose connected by b-glycosidic bounds to other sug-
ars of the oligosaccharide chains [19]. GAL releases
D-galactose from nonreducing ends of oligosaccha-
ride chains of glycoproteins, glycolipids and gly-
cosaminoglycans [19, 20]. GAL with equal intensity
hydrolyzes lactose and O-nitrophenol-B-D-galacto-
pyranoside [21].
The aim of this study was to evaluate the activity
of the lysosomal exoglycosidases FUC and GAL in
the serum of patients with Lyme disease.
Material and methods
Material for the study was serum obtained from venous
blood of patients with Lyme disease, before treatment. The
study included 15 patients (six women and nine men aged
41–63 years, mean age 56 ± 10.43 years) hospitalized in the
Department of Infectious Diseases and Neuroinfections at
the Medical University of Bialystok. Lyme disease was
diagnosed clinically according to the European Center
for Disease Control and Prevention, based on tick biting,
and erythema in place of biting in anamnesis, as well as
two-step serological investigation (positive ELISA and
Western blot tests in direction to Borrelia burgdorferi).
Control serum was obtained from blood collected from
eight healthy adults (four women and four men). Age
range of the control group was 31–71 years (mean age 50 ±
± 13.42 years). The study was approved by the local Com-
mittee for Human Reserch (RI-002/202/2011), and was
performed according to guidelines for good clinical prac-
tice. Venous blood was taken from the cubital veins (with-
out anticoagulant) into sterile tubes, and left for 30 min-
utes at 4°C for clotting and clot retraction. After this time,
the serum was centrifuged at 3,500 × g for 10 minutes at
4°C. The serum was stored at 80°C before use. a-fucosi-
dase (FUC), and b-galactosidase (GAL) activity (pKat/
/ml of blood serum) was determined spectrophotometri-
cally using 4-nitrophenyl-a-L -fucopyranoside and
p-nitrophenyl b-D-galactopyranoside (Sigma–Aldrich) as
substrates, following the method of Chatterjee et al. [22]
as modified by Zwierz et al. [23].
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The results were analyzed by statistical package SPSS®
for Windows PL (SPSS, Chicago, IL, USA) according to
the Mann–Whitney test. The statistical significance of dif-
ferences was regarded to be p < 0.05.
Results
The concentration of GAL and FUC activity in the
serum of patients with Lyme disease was 286.62 ±
± 64.01 pKat/ml for GAL, and 234.59 ± 66.33 pKat/
/ml for FUC, and was 234.95 ± 69.96 pKat/ml for
GAL, and 176.61 ± 30.71 pKat/ml for FUC in the
serum of healthy persons (Figures 1, 2). The concen-
tration of GAL activity in the serum of patients with
Lyme disease was significantly higher (p = 0.029)
compared to the activity in the blood serum of healthy
individuals (Figure 1). There was a trend to increase
the concentration of FUC activity in the serum of
patients with Lyme disease in comparison with the
FUC concentration in the serum of healthy individu-
als (Figure 2).
Discussion
Lyme disease is the commonest tick-borne disease in
Europe [24, 25]. The disease is characterized by
a chronic phase and varied course of the clinical pic-
ture [26]. Lyme disease affects in particular the skin,
central and peripheral nervous system, heart, muscu-
loskeletal system, and joints [2, 25–28]. Iżycka et al.
[29], in examining the expression of CD43 and PSGL
particles-1 on the neutrophils of patients with Lyme
disease, found an increase in the concentration of the
soluble form of PSGL-1 (sPSGL-1). PSGL is a ligand
for P- and E-selectins involved in the first stage of
adhesion, which occurs during margination and rolling
neutrophils. Increasing concentration of sPSGL-1,
by blocking specific membrane ligands on neutro-
phils, leads to inhibition of neutrophils adhesion and
promotes long-term persistence of the inflammato-
ry process [29].
Lyme disease is difficult to diagnose and eradi-
cate [30], because of the unique features of the spiro-
chete Borrelia burgdorferi and high affinity of the spi-
rochete for connective tissue, muscle and nervous tis-
sue [27]. Lyme disease has uncharacteristic symptoms
and can mimic many diseases, which in turn contrib-
utes to errors in diagnosis. Often, the patient is treat-
ed by different specialists, and the late diagnosis re-
duces the chances of spirochete elimination [27, 31].
Lyme disease is diagnosed by serological detection of
the IgG and IgM antibodies directed against Borrelia
burgdorferi antigens. A two-step method is recom-
mended, in which the screening test is an ELISA,
while the confirming test is a Western blot. The test
is performed both in serum and CSF (in the case of
neuroboreliosis) [32–34]. However, even the introduc-
tion of routine testing for Lyme disease and Western
blot confirmatory test does not solve completely the
problems of laboratory diagnosis of Lyme disease.
This is because the test is designed to detect specific
antibodies which may cover antigens derived from
species of Borrelia burgdorferi which do not occur in
diagnosed patients [35].
For routine diagnosis of Lyme disease, we do not
recommend the use of PCR, microscopic examina-
tion or culture. PCR is not sufficiently standardized
and uses a variety of primers and different genes as
starting materials; therefore the results obtained in
different centers are not comparable. Microscopic
Figure 1. Activity of b-galactosidase in serum of patients
with Lyme disease
Figure 2. Activity of a-fucosidase in serum of patients with
Lyme disease
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studies show a high percentage of false results due to
the small number of spirochetes in biological material
[27, 34].
As more and more people suffer from Lyme dis-
ease, alternative methods of diagnosing the disease
are being proposed. Our research is based on the re-
ported changes of the serum [28, 36–38] and urine
[39, 40] exoglycosidases activity in Lyme disease.
Pancewicz et al. [28], in studying the activity of lysos-
omal exoglycosidases in serum and synovial fluid of
patients with Lyme arthritis, noticed a significant in-
crease in the activity of these enzymes in the blood
serum of Lyme disease patients, compared to con-
trols. They observed the largest increase in HEX ac-
tivity. Pancewicz et al. [28] suggested that the activity
of HEX can be used to monitor Lyme disease and
assess the effectiveness of treatment of patients with
Lyme arthritis [28]. Knaś et al. [39] found only a ten-
dency to increase in the activity of the urinary exogly-
cosidases in Lyme disease patients compared to ex-
oglycosidases activity in urine collected from healthy
individuals. Similar results were obtained by Choro-
manska et al. [40], where the only enzyme showing
increased activity in the urine of Lyme disease pa-
tients was HEX. We decided to check the serum ac-
tivity of a-fucosidase and b-galactosidase  the lysoso-
mal exoglycosidases involved in hydrolysis of the oli-
gosaccharide chains of glycolipids, glycoproteins and
proteoglycans [19]. As preliminary studies on the ac-
tivity of GAL and FUC in the serum of patients with
Lyme disease showed a tendency for the activity of
both enzymes in the serum of patients to increase
compared to the sera of healthy individuals [37], we
decided to conduct further studies on a larger group
of patients with Lyme disease to determine whether
the upward trend is not caused only by a small quan-
tity of patients in the tested group. In our present
study, we found that only the activity of b-galactosi-
dase was significantly higher in the serum of patients
with Lyme disease, compared to its activity in healthy
subjects (p = 0.029) (Figure 1), whereas the activity
of a-fucosidase in the serum of patients with Lyme
disease had only a tendency to increase, compared to
the activity of FUC, in the blood serum of healthy
individuals (p = 0.153) (Figure 2).
As mentioned before, Lyme disease promotes
long-term persistence of the inflammatory process.
A typical feature of aging is a chronic low-grade in-
flammatory process, characterized by a general in-
crease in the production of pro-inflammatory cytok-
ines and inflammatory markers [41]. This immunose-
nescence process is explained by an imbalance be-
tween inflammatory and anti-inflammatory networks.
It results in low grade chronic pro-inflammatory sta-
tus and it has been suggested it be called 'inflammag-
ing' [42]. An elevated level of (beta)-galactosidase is
a manifestation of increased residual lysosomal ac-
tivity, which becomes detectable due to the increased
lysosomal content in senescent cells [43]. In our study,
elevated activity of only GAL might be the result of
an accelerated senescence process due to the 'inflam-
maging'. Earlier studies have noted elevated serum
levels of all exoglycosidases including GAL and FUC
in LD [28]. However, this might be due to the very
active synovial inflammation following exoglycosidas-
es release.
Conclusions
1. A significant increase in GAL, but not FUC, ac-
tivity in the serum of patients with Lyme disease
indicates on participation of GAL in increased
remodeling of tissues glycoconjugates connected
with inflammation caused by Borrelia burgdorferi
infection.
2. Increase in serum GAL activity might be helpful
in the diagnosis of Lyme disease, although this
conclusion should be confirmed by a study in
a larger group of patients.
3. An elevated level of b-galactosidase might be
a manifestation of accelerated senescence process
in the course of Lyme disease.
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